Serum levels of cytoplasmic melanoma-associated antigen at diagnosis may predict clinical relapse in neuroblastoma patients

Fabio Morandi(Istituto Giannina Gaslini), Vito Pistoia(Istituto Giannina Gaslini), Lizzia Raffaghello(Istituto Giannina Gaslini), Soldano Ferrone(Massachusetts General Hospital), Maria Valeria Corrias(Boston Children's Hospital), Barbara Carlini(Istituto Giannina Gaslini), Sara Stigliani, Isabella Levreri(Istituto Giannina Gaslini), Paola Bocca(Istituto Giannina Gaslini), Paola Scaruffi(Azienda Ospedaliera S.Maria), Loredana Amoroso(Istituto Giannina Gaslini), Ignazia Prigione(Istituto Giannina Gaslini)
Cancer Immunology Immunotherapy
June 9, 2011
10.1007/s00262-011-1052-0
Cited by 22

Related Papers

Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity.
|PubMed|2002|507
NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo
|Journal of Clinical Investigation|2009|331
Dysregulated metabolism contributes to oncogenesis
|Seminars in Cancer Biology|2015|318
Multiparametric plasma EV profiling facilitates diagnosis of pancreatic malignancy
|Science Translational Medicine|2017|291
Expression of the high molecular weight melanoma-associated antigen by pericytes during angiogenesis in tumors and in healing wounds.
|PubMed|1990|225